title: Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.
abstract: OBJECTIVE
  The purpose of the study is to assess longitudinal changes in general and disease-specific health-related quality-of-life (HRQOL) indices after intensity-modulated radiotherapy (IMRT) monotherapy for patients with localized prostate cancer (PCA).
  
  
  METHODS
  Between 2006 and 2010, 91 patients with localized PCA underwent IMRT monotherapy and were enrolled into this prospective study. At baseline, and at 3, 6, 12, and 24 months after IMRT, the general and prostate-specific HRQOL were estimated using physical (PCS) and mental component summaries (MCS) calculated using the Medical Outcomes Study 8-Item Short Form Health Survey and Expanded Prostate Cancer Index Composite (EPIC).
  
  
  RESULTS
  For 2 years, there were no significant changes in EPIC scores in all subscales of urinary domain, hormonal function, and bother. Bowel and sexual function scores decreased after IMRT and did not return to those at baseline (p = 0.006 and < 0.001, respectively). PCS began to decrease at 3 months after IMRT and then returned to the baseline score at 24 months. In contrast, the MCS score began to significantly increase after IMRT, and thereafter the score remained constant until 24 months (p < 0.001). On multivariate logistic regression analysis, urinary (p = 0.003) and sexual functions (p = 0.0005) at baseline were identified as significant predictors of EPIC urinary irritative/obstructive score and sexual function at 24 months after IMRT.
  
  
  CONCLUSIONS
  Urinary function, including irritative/obstruction symptoms and hormonal function, was not affected by IMRT. However, bowel and sexual function decreased after IMRT. These findings will provide important information for PCA patients considering IMRT.
authors: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Tokyo, Koto-ku, 135-8550, Japan, shinya.yamamoto@jfcr.or.jp.
authors: Shinya
authors: S
authors: Yamamoto
authors: Yasuhisa
authors: Y
authors: Fujii
authors: Hitoshi
authors: H
authors: Masuda
authors: Shinji
authors: S
authors: Urakami
authors: Kazutaka
authors: K
authors: Saito
authors: Takuyo
authors: T
authors: Kozuka
authors: Masahiko
authors: M
authors: Oguchi
authors: Iwao
authors: I
authors: Fukui
authors: Junji
authors: J
authors: Yonese
mesh_terms: D000368:Aged; D015992:Body Mass Index; D002561:Cerebrovascular Disorders / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D006305:Health Status Indicators; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007564:Japan; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000523:psychology* / Q000532:radiotherapy*; D011788:Quality of Life; D050397:Radiotherapy, Intensity-Modulated; D018434:Sickness Impact Profile; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen